Early Follicular Supplementation of Ganirelix in IVF 2004
NCT ID: NCT00461422
Last Updated: 2008-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2004-01-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results.
Consecutive patients are prospectively enrolled and randomly assigned to the study and control groups. Patients with low ovarian reserve or with uterine distortion are excluded from the study. Both groups are treated with recombinant FSH and the flexible GnRH antagonist protocol. Women in the study group are also treated with additional GnRH antagonist 0.25 mg/day on day 1, 2 and 3 of the menstrual cycle.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
Ganirelix
sc injection of Ganirelix 0.25 mg per day
2
Standard Flexible antagonist protocol
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ganirelix
sc injection of Ganirelix 0.25 mg per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* IVF candidate
* failure of previous IVF attempt
Exclusion Criteria
* untreated distortion of uterine cavity
* medical contraindication for IVF treatment
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon
INDUSTRY
The Baruch Padeh Medical Center, Poriya
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yohnny S Younis, MD
Role: PRINCIPAL_INVESTIGATOR
The Ministry of Health, Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Baruch Padeh medical center, Poriya
Tiberias, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
soltsman2004.CTIL
Identifier Type: -
Identifier Source: org_study_id